A detailed history of Bank Of America Corp transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 85,007 shares of GRTS stock, worth $1,700. This represents 0.0% of its overall portfolio holdings.

Number of Shares
85,007
Previous 85,339 0.39%
Holding current value
$1,700
Previous $219,000 76.26%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.62 - $2.35 $205 - $780
-332 Reduced 0.39%
85,007 $52,000
Q1 2024

May 15, 2024

SELL
$1.96 - $2.9 $200,294 - $296,353
-102,191 Reduced 54.49%
85,339 $219,000
Q4 2023

Feb 14, 2024

BUY
$1.28 - $2.85 $186,679 - $415,652
145,843 Added 349.85%
187,530 $382,000
Q2 2023

Aug 14, 2023

SELL
$1.66 - $3.03 $1.69 Million - $3.09 Million
-1,018,551 Reduced 96.07%
41,687 $81,000
Q1 2023

May 12, 2023

BUY
$2.13 - $3.74 $1.99 Million - $3.49 Million
934,149 Added 740.86%
1,060,238 $2.95 Million
Q4 2022

Feb 10, 2023

BUY
$2.17 - $3.92 $153,748 - $277,739
70,852 Added 128.27%
126,089 $435,000
Q3 2022

Nov 14, 2022

BUY
$2.46 - $4.75 $70,110 - $135,375
28,500 Added 106.59%
55,237 $142,000
Q2 2022

Aug 12, 2022

SELL
$1.77 - $4.34 $85,745 - $210,246
-48,444 Reduced 64.44%
26,737 $64,000
Q1 2022

May 16, 2022

SELL
$4.03 - $12.19 $633,640 - $1.92 Million
-157,231 Reduced 67.65%
75,181 $310,000
Q4 2021

Feb 08, 2022

BUY
$8.76 - $13.71 $1.85 Million - $2.9 Million
211,548 Added 1013.94%
232,412 $2.99 Million
Q3 2021

Nov 15, 2021

BUY
$6.41 - $13.54 $45,434 - $95,971
7,088 Added 51.45%
20,864 $225,000
Q2 2021

Sep 13, 2021

BUY
$8.13 - $10.2 $111,998 - $140,515
13,776 New
13,776 $125,000

Others Institutions Holding GRTS

About Gritstone bio, Inc.


  • Ticker GRTS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,006,896
  • Market Cap $1.46M
  • Description
  • Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...
More about GRTS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.